JNJ Stock Forecast & Price Target

Johnson & Johnson demonstrated robust performance in its innovative medicine and medtech divisions, with innovative medicine revenues reaching $15.20 billion, surpassing consensus expectations and driven by strong growth in core therapeutic areas. The company raised its full-year 2025 sales guidance to a range of $93.2 billion to $93.6 billion, reflecting operational strength and favorable currency impacts, indicating a positive trajectory for future earnings. Additionally, JNJ's MedTech division reported revenues of $8.54 billion, exceeding estimates due to strong performance across all segments, further reinforcing solid growth expectations for the latter half of 2025 and into 2026.

The outlook for Johnson & Johnson's stock is negatively influenced by persistently declining sales in key divisions, particularly within the MedTech segment, which faces significant competitive pressures and a downturn in Orthopedics sales attributed to market dynamics and restructuring initiatives. Additionally, the pharmaceutical pipeline's slower-than-expected organic growth, compounded by impending losses of exclusivity for major drugs, raises concerns about the company's ability to achieve projected revenue targets, with estimates indicating less than $57 billion in revenue for 2025. Coupled with ongoing litigation costs and potential disruptions from M&A integration, these factors create substantial risks to JNJ’s future financial performance and investor confidence.